文献速递肝病

代谢功能障碍与酒精相关性肝病:是否需要不同的治疗选择

MetALD: Does it require a different therapeutic option?
PubMed 文献 · Hepatology · 2024-05-31

本综述讨论代谢功能障碍相关脂肪性肝病(MASLD)与代谢功能障碍和酒精相关性肝病(MetALD)的内源性与外源性风险,提出MetALD的治疗策略包括生物心理社会干预、戒酒策略(含酒精使用障碍药物)及审慎使用脂肪性肝病治疗药物,并指出目前尚不清楚MetALD是否需要独特药物或联合方案,需在精心设计的包容性临床试验中进一步明确MASLD相关疗法的安全性与获益。

要点

  • MetALD被定义为MASLD与酒精相关性肝病的重叠病变。
  • MASLD治疗药物通常未在持续显著饮酒患者中研究。
  • GLP-1受体激动剂与PPARγ激动剂在MASLD中证据最多,酒精性肝病试验药物匮乏。

核心结论

  • 从现有研究尚不清楚MetALD是否需要独特治疗药物或联合方案。
  • 进一步明确MASLD相关疗法的安全性与获益对推进MetALD治疗至关重要,需在精心设计的包容性临床试验中进行。

研究设计与样本

  • 本综述讨论MASLD与MetALD的内源性和外源性风险及治疗策略。

主要发现

  • MASLD各阶段有广泛在研治疗药物,但通常未在持续显著饮酒患者中研究。
  • MetALD有前景的治疗包括基于肠促胰岛素的疗法、FGF21激动剂、甲状腺激素受体β激动剂、钠-葡萄糖共转运蛋白2抑制剂及调节从头脂肪生成的药物。
  • 目前胰高血糖素样肽1受体激动剂和过氧化物酶体增殖物激活受体γ激动剂在MASLD中的支持文献最多,酒精相关性肝病试验药物匮乏。

关键数值与推荐

  • 新指南将MetALD命名为MASLD与酒精相关性肝病的重叠病变。

临床怎么用

  • MetALD的合理治疗策略包括生物心理社会干预、戒酒策略(含酒精使用障碍药物)及审慎使用脂肪性肝病治疗药物。

局限性

  • MASLD治疗药物通常未在持续显著饮酒患者中研究。
  • 从现有研究尚不清楚MetALD是否需要独特治疗药物或联合方案。
  • 酒精相关性肝病试验药物匮乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New guidelines for the definitions of steatotic liver disease have named the entity of metabolic dysfunction and alcohol-associated liver disease (MetALD) as an overlap condition of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease. There is a broad range of therapeutics in all stages of development for MASLD, but these therapeutics, in general, have not been studied in patients with significant ongoing alcohol use. In this review, we discuss the current understanding of the endogenous and exogenous risks for MASLD and MetALD. Rational strategies for therapeutic intervention in MetALD include biopsychosocial interventions, alcohol use cessation strategies, including the use of medications for alcohol use disorder, and judicious use of therapeutics for steatotic liver disease. Therapeutics with promise for MetALD include incretin-based therapies, FGF21 agonists, thyroid hormone receptor beta agonists, sodium-glucose co-transporter 2 inhibitors, and agents to modify de novo lipogenesis. Currently, glucagon-like peptide 1 receptor agonists and peroxisome proliferator-activated receptor γ agonists have the largest body of literature supporting their use in MASLD, and there is a paucity of agents in trials for alcohol-associated liver disease. From existing studies, it is not clear if unique therapeutics or a combinatorial approach are needed for MetALD. Further elucidation of the safety and benefits of MASLD-related therapies is of paramount importance for advancing therapeutics for MetALD in carefully designed inclusive clinical trials.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Marek GW, Malhi H. MetALD: Does it require a different therapeutic option? Hepatology. 2024. PMID: 38820071. doi:10.1097/HEP.0000000000000935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。